
Feds invite practices to test e-prior auth; Alzheimer's light-and-sound device misses main goal; fasting windows add little for liver fat — Morning Medical Update
Key Takeaways
- ONC/CMS are enrolling payers, providers, hospitals, EHR vendors, and intermediaries to validate ePA workflows for high-volume services, with voluntary participation that does not imply certification or compliance.
- Interoperability and prior authorization rules will require ePA support by Jan. 1 for Medicare Advantage, Medicaid managed care, CHIP, and federally facilitated exchange plans and issuers.
The top news stories in medicine today.
Feds invite practices to test electronic prior authorization
Sign-up closes Nov. 20, ahead of a Jan. 1 payer deadline.
The Office of the National Coordinator for Health Information Technology (ONC) and the Centers for Medicare & Medicaid Services (CMS) are
Testing will run in 10- to 12-week sprints in production-like environments, built around high-volume, high-priority clinical services that require prior authorization. Drummond Group operates FHIRplace, the virtual environment where participants test with their partners. First-round space is limited, and organizations should express interest by Nov. 20. ONC and CMS said they encourage organizations of all sizes to take part, including smaller organizations and those serving rural communities. Participation is voluntary and does not constitute certification or a determination of compliance with CMS requirements.
“Federal regulations and industry standards have laid important groundwork for ePA, but our work is not done,” said Tom Keane, M.D., national coordinator for health information technology. On Jan. 1, Medicare Advantage, Medicaid managed care and Children's Health Insurance Program plans and plan issuers on the federal exchanges
A flicker of HOPE for an Alzheimer's device
The trial missed its primary endpoint, but the company will seek FDA authorization for early disease.
An at-home device that delivers 40-hertz light and sound stimulation in daily one-hour sessions did not meet its primary endpoint in a 12-month pivotal trial of 663 patients with mild or moderate Alzheimer's disease, Cognito Therapeutics
Among 395 patients with mild disease, the device slowed decline 56% on a measure of daily function and 47% on a dementia severity scale compared with sham, though the company noted those p-values are not adjusted for multiple comparisons. The 268 patients with moderate disease showed no clinical benefit. Adverse device effects were reported in 18.3% of patients using the device, and seizures occurred in 0.9% of device users compared with 0.3% of the sham group.
The approach grew out of research in the lab of Li-Huei Tsai, a Cognito co-founder, at
Liver fat cares about the scale, not the clock
Losing at least 5% of body weight drove the biggest drops in a 197-person trial.
Adding time-restricted eating to a Mediterranean diet education program did not reduce liver fat more than the program alone in a
Liver fat, measured by MRI, fell in all three fasting groups, but the differences from usual care were not statistically significant, and the timing of the window made no difference. The largest reductions came among participants who lost at least 5% of their body weight, a threshold about 40% to 45% of those fasting reached, and among those who already had fatty liver at the start.
“The most important factor seems to be choosing a strategy that facilitates clinically significant weight loss and can be sustained over time,” the researchers said. The findings, a secondary analysis of a trial previously published in Nature Medicine, appear in JHEP Reports. An observational study this fall
Here's
Related to this article









